We are live on ! Find out more
SVA

Sinovac Biotech, Ltd

Delisted

SVA was delisted on the 22nd of February, 2019.

37 hedge funds and large institutions have $66.5M invested in Sinovac Biotech, Ltd in 2015 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 13 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% more capital invested

Capital invested by funds: $62.6M → $66.5M (+$3.95M)

8% less funds holding

Funds holding: 4037 (-3)

23% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 13

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

Holders
37
Holders Change
-3
Holders Change %
-7.5%
% of All Funds
1%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
10
Reduced
13
Closed
7
Calls
$11K
Puts
Net Calls
+$11K
Net Calls Change
+$89K
Name Holding Trade Value Shares
Change
Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$21.4M -$2.65M -502,106 -11%
O
2
OrbiMed
New York
$14M
Renaissance Technologies
3
Renaissance Technologies
New York
$6.63M +$407K +77,000 +6%
PRCM
4
Pine River Capital Management
Minnesota
$5.75M
Fidelity International
5
Fidelity International
Bermuda
$5.73M
BFA
6
BlackRock Fund Advisors
California
$3.83M +$127K +24,093 +3%
First Manhattan
7
First Manhattan
New York
$3.17M +$3.19M +603,666 New
Zurich Cantonal Bank
8
Zurich Cantonal Bank
Switzerland
$944K
Deutsche Bank
9
Deutsche Bank
Germany
$932K +$60.2K +11,389 +7%
FIM
10
Freedom Investment Management
Connecticut
$826K +$241K +45,549 +41%
Invesco
11
Invesco
Georgia
$510K -$102K -19,381 -17%
California Public Employees Retirement System
12
California Public Employees Retirement System
California
$398K
Morgan Stanley
13
Morgan Stanley
New York
$352K -$167K -31,652 -32%
CS
14
Credit Suisse
Switzerland
$255K +$42.8K +8,095 +20%
Two Sigma Advisers
15
Two Sigma Advisers
New York
$249K -$21.7K -4,100 -8%
ProShare Advisors
16
ProShare Advisors
Maryland
$234K -$951 -180 -0.4%
Two Sigma Investments
17
Two Sigma Investments
New York
$219K -$465 -88 -0.2%
VAM
18
Verity Asset Management
North Carolina
$188K +$96.2K +18,213 +103%
Goldman Sachs
19
Goldman Sachs
New York
$185K -$296K -56,026 -61%
PIM
20
Platinum Investment Management
Australia
$159K +$161K +30,400 New
Susquehanna International Group
21
Susquehanna International Group
Pennsylvania
$122K -$10.8K -2,042 -8%
PP
22
PDT Partners
New York
$122K +$68.7K +13,000 +126%
Geode Capital Management
23
Geode Capital Management
Massachusetts
$118K +$27.3K +5,166 +30%
VKH
24
Virtu KCG Holdings
New York
$93K +$93.6K +17,720 New
Citigroup
25
Citigroup
New York
$43K +$4.9K +928 +13%

SVA Hedge Fund Activity: Q2 2015 in Review

37 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q2 2015, worth a combined $66.5M — up 6.3% from $62.6M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of SVA and 5 opened new positions — a net loss of 2 holders — while 13 trimmed existing stakes and 10 added.

The largest buyer was First Manhattan, opening a new position worth an estimated $3.19M. The largest seller was Wellington Management Group, cutting an estimated $2.65M.

  • 37 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q2 2015, down from 40 in Q1 2015.
  • Funds reported $66.5M of Sinovac Biotech, Ltd stock for Q2 2015, up 6.3% quarter-over-quarter.
  • 5 funds opened new Sinovac Biotech, Ltd positions in Q2 2015 and 7 closed out, a net change of -2 holders.
  • The largest Sinovac Biotech, Ltd buyer in Q2 2015 was First Manhattan, an estimated $3.19M added.
  • The largest Sinovac Biotech, Ltd seller in Q2 2015 was Wellington Management Group, an estimated $2.65M sold.

Based on aggregated 13F filings for Q2 2015.